Brief: Rua Bioscience Says Sales For Q1 FY26 Are A Record
02/11/2025 20:09
Nov 3 (Reuters) - Rua Bioscience RUA.NZ: SALES FOR Q1 FY26 ARE A RECORD RENOUCENABLE RIGHTS ISSUE OF 1 NEW SHARES FOR EVERY 3 EXISTING SHARES TO RAISE UP TO NZ$2MILLION ISSUE PRICE UNDER RIGHTS OFFER NZ$0.025 PER SHARE Further company coverage: RUA.NZ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rua Bioscience
See all newsBrief: Rua Bioscience Partners With Curaleaf Laboratories For UK Distribution
Brief: Rua Bioscience Partners To Supply Medicinal MDMA In New Zealand
Brief: Pharmala Biotech Holdings Rua Bioscience And Pharmala Biotech Partner To Supply Medicinal Mdma In New Zealand
Brief: Rua Bioscience Posts Preliminary Unaudited Annual Results
New Zealand's Rua Bioscience FY customer revenue jumps on Australia, NZ growth